Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Stock Has Average Price Target of $18.20

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $18.20.

Several research firms recently issued reports on BWAY. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. Zacks Research downgraded Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings lowered Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, August 19th. BTIG Research reissued a “buy” rating and issued a $20.00 target price on shares of Brainsway in a report on Thursday, September 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Brainsway in a research note on Tuesday, September 8th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Brainsway during the first quarter worth about $40,000. Ballast Advisors LLC bought a new position in Brainsway in the 1st quarter valued at approximately $55,000. Royal Bank of Canada boosted its position in Brainsway by 84.2% during the 1st quarter. Royal Bank of Canada now owns 15,490 shares of the company’s stock worth $206,000 after buying an additional 7,080 shares during the period. NewEdge Advisors LLC grew its holdings in Brainsway by 434.6% during the 2nd quarter. NewEdge Advisors LLC now owns 18,830 shares of the company’s stock worth $292,000 after acquiring an additional 15,308 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in Brainsway during the 1st quarter worth approximately $206,000. 30.11% of the stock is currently owned by institutional investors.

Brainsway Trading Down 2.3%

Shares of BWAY opened at $11.62 on Friday. The company has a market cap of $467.59 million, a price-to-earnings ratio of 26.41 and a beta of 1.29. The company’s fifty day simple moving average is $14.25 and its 200 day simple moving average is $14.73. Brainsway has a 1-year low of $7.14 and a 1-year high of $17.40.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. Brainsway had a return on equity of 12.74% and a net margin of 15.65%.The firm had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.54 million. As a group, research analysts forecast that Brainsway will post 0.33 earnings per share for the current year.

Brainsway Company Profile

BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive treatments for brain disorders. Its primary technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is delivered through specialized treatment systems and helmet-like coils.

The company’s Deep TMS platform is used by healthcare providers in the treatment of major depressive disorder, obsessive-compulsive disorder and smoking addiction, subject to applicable regulatory clearances and local treatment guidelines.